Affimed has filed a patent for a trispecific antibody construct targeting CD16A on immune cells, various antigens, and target cell antigens. The construct includes specific binding domains for each target. The invention covers nucleic acids, vectors, methods, pharmaceutical compositions, and medical uses. GlobalData’s report on Affimed gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Affimed, Personalized cancer vaccines was a key innovation area identified from patents. Affimed's grant share as of January 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Trispecific antibody construct for targeting immune effector and target cells
A trispecific antibody construct has been claimed in a filed patent (Publication Number: US20230365709A1). The construct comprises three binding domains - one binding to CD16A on an immune effector cell, another binding to an antigen on the same cell, and the third binding to an antigen on a target cell. The first binding domain specifically binds to CD16A, with an epitope including Y158 of SEQ ID NO: 449. The construct aims to reduce or prevent simultaneous binding of two immune effector cells while binding to a target cell and one immune effector cell simultaneously. Additionally, the construct includes a half-life extension domain and can be monovalent or bivalent for different binding domains.
Furthermore, the patent claims cover various configurations of the antibody construct, including fusion of binding domains, arrangement of hinge and CH domains, and specific amino acid sequences. The construct is designed to induce lower levels of fratricide compared to control constructs and anti-CD38 antibodies. It is intended for use in therapy for diseases like proliferative diseases, tumorous diseases, viral diseases, and immunological disorders. The patent also includes claims for nucleic acid molecules encoding the construct, vectors, host cells, methods of production, pharmaceutical compositions, and kits containing the antibody construct. A method for simultaneously binding a target cell and an immune effector cell is also described, focusing on target cell-specific activation of the immune effector cell.
To know more about GlobalData’s detailed insights on Affimed, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
